Latest Financial Health News

TPG Telecom has announced a substantial special dividend and capital reduction totaling approximately AUD 3 billion, pending shareholder approval at the upcoming EGM.

Nanosonics Limited has announced a $20 million on-market share buy-back program for FY26, underscoring its robust financial health and confidence in future growth driven by new product innovations.

LCL Resources Limited faces suspension from ASX trading due to failure to lodge a required periodic report on time, raising questions about the company’s compliance and operational transparency.

West African Resources Limited reported a robust quarterly cash flow with strong operating inflows and substantial cash reserves, underscoring its solid financial footing amid ongoing exploration investments.

Infinity Mining Limited reported a net cash outflow of A$143,000 for the September quarter, with cash reserves dwindling to A$30,000. The company is pursuing cost-saving measures and an imminent capital raising to secure its short-term future.

True North Copper reported significant copper-gold and copper-cobalt-silver discoveries in its September 2025 quarter, reinforcing its growth strategy and financial strength heading into 2026.

Saunders International anticipates a weaker first half in FY26 amid ongoing operational challenges but gains momentum with major contracts and strategic expansion into New South Wales.

Echelon Resources reported a solid quarter with production gains at Maari and Mahato fields, supported by new wells and a strategic gas sales agreement, while maintaining shareholder returns through dividends.

Cobram Estate Olives Limited has reported a record-breaking FY2025, driven by strong sales growth in Australia and the USA, alongside a $178 million equity raise to accelerate its Californian olive grove expansion.

Otto Energy reported an 11% rise in oil production and a solid US$2 million net operating cash inflow in Q3 2025, alongside key executive and board changes.

Alterity Therapeutics reports strengthened efficacy signals for ATH434 in Multiple System Atrophy and secures a robust cash position to fuel upcoming Phase 3 trials.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.